Serum Levels of Substance P and Response to Antidepressant Pharmacotherapy

Abstract

Substance P (SP) is possibly involved in the etiopathology of affective disorders. Here we investigated the relationship of SP serum levels and response to antidepressant drug therapy. SP serum levels were determined before and during a 9-week drug trial in 40 depressed patients treated with paroxetine in combination with either lamotrigine (n = 20) or placebo (n = 20). Responders (n = 18) and non-responders (n = 22) significantly differed in SP serum levels: responders started with higher SP levels that decreased during drug therapy, whereas non-responders had lower SP levels that increased at the beginning. There were no differences between patients with adjunct lamotrigine or placebo. These preliminary data indicate that SP serum levels might be related to response to antidepressant drug therapy. Further studies have to substantiate this finding.

Psychiatric disorders and general medical conditions: implications for the clinician

“…47 While SSRI treatment of depression does not specifically target neuropeptide receptors, recent preliminary evidence suggests that higher pre-treatment serum substance P levels are associated with clinical response to SSRIs in depression. 48 It remains to be investigated whether SSRI treatment in asymptomatic HIV delays disease progression in association with levels of substance P. To what extent substance P is a reliable predictor of treatment response to SSRIs in HIV requires further exploration. Once again, the relationship between HIV and psychiatric illness is a bidirectional one.…”

Acne vulgaris, probiotics and the gut-brain-skin axis - back to the future?

“…Indeed, even minute elevations in circulating substance P can lead to anxiety, depression and aggression [86]. Conversely, those who respond to antidepressant pharmacotherapy are known to have declines in serum substance P in conjunction with improved mood states [87]. Thirty years have passed since it was discovered that biologically active peptides such as substance P not only communicate within the gut, brain and skin, they are also of common embryonic origin [88].…”

Intestinal microbiota, probiotics and mental health: from Metchnikoff to modern advances: part III – convergence toward clinical trials

“…Indeed, even very slight elevations in circulating substance P can lead to anxiety, depression and aggression [81]. Conversely, those who respond to antidepressant pharmacotherapy are known to have declines in serum substance P in conjunction with improved mood states [82]. An additional area of relevance between emerging probiotic research and depression/anxiety involves the cannabinoid receptors.…”